Double maintains 3 strategies that include APLS - Apellis Pharmaceuticals, Inc.
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 52.95% | $4.85B | 0.35% |
GNOM | 49.41% | $40.65M | 0.5% |
IBB | 49.16% | $5.22B | 0.45% |
ARKG | 45.58% | $944.78M | 0.75% |
PBE | 44.51% | $214.12M | 0.58% |
IWO | 44.05% | $11.36B | 0.24% |
IWC | 43.26% | $766.88M | 0.6% |
IWM | 42.62% | $63.95B | 0.19% |
VTWO | 42.59% | $12.07B | 0.07% |
XHE | 41.96% | $171.93M | 0.35% |
BBH | 41.81% | $327.42M | 0.35% |
KJUL | 41.72% | $113.35M | 0.79% |
CPRJ | 41.48% | $48.43M | 0.69% |
KOMP | 41.09% | $2.20B | 0.2% |
PAWZ | 41.00% | $58.77M | 0.5% |
VBK | 40.93% | $18.33B | 0.07% |
QQQJ | 40.86% | $610.08M | 0.15% |
ISCG | 40.73% | $645.00M | 0.06% |
ICVT | 40.72% | $2.46B | 0.2% |
SCHA | 40.60% | $16.91B | 0.04% |
Yahoo
Apellis Pharmaceuticals (APLS) has had a difficult Q1 as charitable foundation funding gaps and weak
Yahoo
Scotiabank analyst Greg Harrison lowered the firm’s price target on Apellis (APLS) to $20 from $28 and keeps a Sector Perform rating on the shares. The company had a weak Q1, with Syfovre revenues in geographic atrophy missing expectations due to underfunding of retinal therapeutics co-pay assistance programs and inventory draw down, the analyst tells investors. The firm is lowering its price target on the stock to reflect its updated expectations for Syfovre sales. Published first on TheFly – t
Yahoo
Investing.com -- Raymond James downgraded Apellis Pharmaceuticals (NASDAQ:APLS) to Outperform from Strong Buy following a first-quarter sales miss and rising concerns over volatility in the company’s revenue outlook.
Yahoo
We recently compiled a list of the 11 Stocks That Will Bounce Back According To Analysts. In this article, we are going to take a look at where Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) stands against the other stocks that will bounce back. Major US indexes finished in the green on Wednesday, May 7, after a volatile […]
Yahoo
APLS stock falls as it reports weaker-than-expected first-quarter 2025 results, wherein both earnings and revenues miss estimates.
Yahoo
Apellis Pharmaceuticals Inc (APLS) reports robust market share growth for SYFOVRE despite revenue shortfalls and co-pay assistance hurdles.
Current Value
$16.351 Year Return
Current Value
$16.351 Year Return
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
ROIV | 45.74% | $7.68B | -5.70% | 0.00% |
EYPT | 44.04% | $393.60M | -54.31% | 0.00% |
BEAM | 43.24% | $1.73B | -27.49% | 0.00% |
NTLA | 43.11% | $836.43M | -69.14% | 0.00% |
ARWR | 40.53% | $2.12B | -38.64% | 0.00% |
DNLI | 40.46% | $2.06B | -30.04% | 0.00% |
CYTK | 39.84% | $3.56B | -50.20% | 0.00% |
CRSP | 39.36% | $3.14B | -34.78% | 0.00% |
PAX | 38.79% | $1.95B | -4.03% | 6.16% |
CLDX | 38.51% | $1.33B | -49.67% | 0.00% |
QTRX | 38.47% | $174.73M | -74.06% | 0.00% |
ICUI | 38.45% | $3.46B | +32.25% | 0.00% |
IMVT | 38.30% | $2.36B | -55.78% | 0.00% |
DAWN | 38.29% | $624.39M | -61.57% | 0.00% |
COGT | 38.24% | $543.09M | -36.14% | 0.00% |
RXRX | 37.91% | $1.73B | -55.31% | 0.00% |
ACLX | 37.80% | $3.22B | +10.72% | 0.00% |
ZYME | 37.79% | $810.02M | +22.92% | 0.00% |
BARK | 37.77% | $220.39M | +1.61% | 0.00% |
SXI | 37.59% | $1.87B | -10.70% | 0.82% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -32.36% | $361.41M | 1.43% |
VIXY | -31.01% | $109.64M | 0.85% |
TAIL | -28.16% | $140.49M | 0.59% |
CLIP | -14.29% | $1.50B | 0.07% |
ULST | -13.72% | $637.77M | 0.2% |
XHLF | -13.50% | $1.46B | 0.03% |
TBIL | -10.95% | $5.76B | 0.15% |
USDU | -10.20% | $173.44M | 0.5% |
GBIL | -9.21% | $6.17B | 0.12% |
FTSD | -8.25% | $212.46M | 0.25% |
TFLO | -8.16% | $7.06B | 0.15% |
XONE | -8.15% | $603.24M | 0.03% |
LDUR | -8.06% | $849.09M | 0.5% |
IVOL | -7.73% | $353.94M | 1.02% |
XBIL | -7.63% | $782.40M | 0.15% |
TPMN | -7.29% | $31.54M | 0.65% |
BILZ | -7.12% | $876.85M | 0.14% |
USFR | -5.88% | $18.91B | 0.15% |
SGOV | -5.33% | $45.91B | 0.09% |
SPTS | -5.27% | $5.76B | 0.03% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
LITB | -12.15% | $21.28M | -72.45% | 0.00% |
K | -10.91% | $28.49B | +32.17% | 2.77% |
FATBB | -9.95% | $50.77M | -11.65% | 9.83% |
VSA | -9.64% | $7.04M | -49.24% | 0.00% |
FMTO | -7.89% | $45.74M | -99.96% | 0.00% |
CORT | -7.14% | $7.78B | +166.38% | 0.00% |
MO | -6.75% | $97.80B | +26.35% | 6.94% |
ED | -6.08% | $36.75B | +5.26% | 3.28% |
RPRX | -5.73% | $13.96B | +18.79% | 2.55% |
MCK | -5.69% | $88.42B | +27.17% | 0.39% |
CYCN | -4.89% | $9.37M | +2.39% | 0.00% |
AEP | -4.34% | $54.28B | +9.80% | 3.61% |
EXC | -4.13% | $43.84B | +12.45% | 3.59% |
NEUE | -3.91% | $62.05M | +13.56% | 0.00% |
PPC | -3.88% | $11.21B | +41.54% | 0.00% |
CBOE | -3.83% | $22.95B | +20.67% | 1.12% |
PULM | -3.12% | $23.82M | +239.64% | 0.00% |
COR | -2.58% | $55.43B | +28.90% | 0.56% |
PRPO | -2.16% | $10.84M | +15.14% | 0.00% |
KR | -1.71% | $44.68B | +24.17% | 1.89% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
CORN | -0.06% | $49.57M | 0.2% |
USL | 0.08% | $41.76M | 0.85% |
CTA | -0.22% | $1.05B | 0.76% |
USO | -0.27% | $956.18M | 0.6% |
IBTH | 0.45% | $1.53B | 0.07% |
WEAT | 0.61% | $115.83M | 0.28% |
OILK | 0.70% | $63.21M | 0.69% |
VGSH | -0.72% | $22.38B | 0.03% |
JMST | 0.79% | $3.65B | 0.18% |
TBLL | -0.88% | $2.46B | 0.08% |
IBD | -0.88% | $380.12M | 0.43% |
SOYB | 0.95% | $25.54M | 0.22% |
IBDQ | 1.00% | $3.08B | 0.1% |
SCHO | 1.09% | $10.87B | 0.03% |
KCCA | -1.25% | $97.18M | 0.87% |
STPZ | -1.30% | $446.46M | 0.2% |
BNO | -1.33% | $86.13M | 1% |
FTSM | -1.67% | $6.54B | 0.45% |
DBO | 1.75% | $182.54M | 0.77% |
CANE | 1.79% | $10.71M | 0.29% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
LMT | -0.02% | $108.98B | +0.07% | 2.79% |
HUSA | -0.11% | $9.73M | -55.71% | 0.00% |
BULL | 0.19% | $5.67B | +11.22% | 0.00% |
CHRW | -0.23% | $11.72B | +18.76% | 2.46% |
ZCMD | -0.29% | $32.45M | -11.38% | 0.00% |
FROG | 0.30% | $4.95B | +31.26% | 0.00% |
CEG | -0.40% | $89.14B | +31.46% | 0.51% |
WEC | 0.43% | $33.48B | +22.69% | 3.29% |
CCEC | 0.51% | $1.02B | +3.91% | 2.71% |
PRA | 0.59% | $1.19B | +58.17% | 0.00% |
VHC | 0.63% | $34.69M | +74.89% | 0.00% |
SAVA | 0.77% | $99.03M | -90.49% | 0.00% |
CME | 0.81% | $98.74B | +28.80% | 3.84% |
OCFT | -0.84% | $265.28M | +232.26% | 0.00% |
CHD | -1.00% | $23.29B | -11.36% | 1.23% |
ARLP | 1.02% | $3.42B | +17.02% | 10.52% |
TPB | 1.19% | $1.29B | +113.31% | 0.40% |
MSIF | 1.21% | $715.25M | +28.42% | 7.05% |
STG | -1.23% | $27.05M | -37.35% | 0.00% |
T | -1.28% | $196.66B | +57.98% | 4.07% |